Kanishk Kumar: Thalassemia Pipeline 2025 Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared a post on LinkedIn:
”Thalassemia Pipeline 2025: Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Thalassemia, a group of inherited blood disorders causing reduced hemoglobin synthesis and chronic anemia, is advancing with innovative therapies in 2025. The Thalassemia Pipeline features 25+ pharmaceutical firms developing 28+ investigational medications, from gene editing to small molecules, aimed at increasing hemoglobin levels, reducing transfusion dependency, and improving quality of life for patients with varying severity.
Key Developments in Thalassemia Treatment:
Etavopivat by Novo Nordisk, a PKR activator in Phase III, aims to improve red blood cell health and reduce anemia in thalassemia by enhancing oxygen affinity and decreasing hemolysis.
CS-101 by Correct Sequence Therapeutics, a gene editing therapy in Phase I, reactivates fetal hemoglobin production for a potential lifetime cure using the patient’s own stem cells.
Leading Thalassemia Companies include Novo Nordisk , Kind Pharmaceuticals LLC, Correct Sequence Therapeutics , Editas Medicine, San Rocco Therapeutics, Lantu Biopharma, Regeneron , Kanglin Biotec, Shanghai BDgene Co., Ltd., BioRay Pharmaceutical , Celgene, Mabwell , among others.
Promising therapies include Etavopivat, AND017, CS101, among others.
DelveInsight’s comprehensive report on the Thalassemia Pipeline Analysis 2025․՛՛
Stay updated with Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means.
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC